Switch theme
Sign up to access all valuation multiples
WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.
2014
12.6K+
LTM Revenue $3.0B
LTM EBITDA $1.0B
$12.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Wuxi Biologics has a last 12-month revenue (LTM) of $3.0B and a last 12-month EBITDA of $1.0B.
In the most recent fiscal year, Wuxi Biologics achieved revenue of $2.4B and an EBITDA of $821M.
Wuxi Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Wuxi Biologics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0B | XXX | $2.4B | XXX | XXX | XXX |
| Gross Profit | $1.2B | XXX | $977M | XXX | XXX | XXX |
| Gross Margin | 41% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $1.0B | XXX | $821M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBIT | $784M | XXX | $635M | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $547M | XXX | $428M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Wuxi Biologics's stock price is HKD 25 (or $3).
Wuxi Biologics has current market cap of HKD 102B (or $13.0B), and EV of HKD 95.2B (or $12.2B).
See Wuxi Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.2B | $13.0B | XXX | XXX | XXX | XXX | $0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Wuxi Biologics has market cap of $13.0B and EV of $12.2B.
Wuxi Biologics's trades at 5.1x EV/Revenue multiple, and 14.8x EV/EBITDA.
Equity research analysts estimate Wuxi Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Wuxi Biologics has a P/E ratio of 25.8x.
See valuation multiples for Wuxi Biologics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13.0B | XXX | $13.0B | XXX | XXX | XXX |
| EV (current) | $12.2B | XXX | $12.2B | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | 13.0x | XXX | 14.8x | XXX | XXX | XXX |
| EV/EBIT | 16.9x | XXX | 19.1x | XXX | XXX | XXX |
| EV/Gross Profit | 10.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 25.8x | XXX | 30.2x | XXX | XXX | XXX |
| EV/FCF | 75.9x | XXX | 74.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWuxi Biologics's last 12 month revenue growth is 16%
Wuxi Biologics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $27K for the same period.
Wuxi Biologics's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Wuxi Biologics's rule of X is 73% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Wuxi Biologics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | 48% | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 73% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $27K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wuxi Biologics acquired XXX companies to date.
Last acquisition by Wuxi Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . Wuxi Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Wuxi Biologics founded? | Wuxi Biologics was founded in 2014. |
| Where is Wuxi Biologics headquartered? | Wuxi Biologics is headquartered in Hong Kong. |
| How many employees does Wuxi Biologics have? | As of today, Wuxi Biologics has 12.6K+ employees. |
| Who is the CEO of Wuxi Biologics? | Wuxi Biologics's CEO is Dr. Chen Zhisheng. |
| Is Wuxi Biologics publicy listed? | Yes, Wuxi Biologics is a public company listed on HKG. |
| What is the stock symbol of Wuxi Biologics? | Wuxi Biologics trades under 02269 ticker. |
| When did Wuxi Biologics go public? | Wuxi Biologics went public in 2017. |
| Who are competitors of Wuxi Biologics? | Similar companies to Wuxi Biologics include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Wuxi Biologics? | Wuxi Biologics's current market cap is $13.0B |
| What is the current revenue of Wuxi Biologics? | Wuxi Biologics's last 12 months revenue is $3.0B. |
| What is the current revenue growth of Wuxi Biologics? | Wuxi Biologics revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Wuxi Biologics? | Current revenue multiple of Wuxi Biologics is 4.5x. |
| Is Wuxi Biologics profitable? | Yes, Wuxi Biologics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Wuxi Biologics? | Wuxi Biologics's last 12 months EBITDA is $1.0B. |
| What is Wuxi Biologics's EBITDA margin? | Wuxi Biologics's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Wuxi Biologics? | Current EBITDA multiple of Wuxi Biologics is 13.0x. |
| What is the current FCF of Wuxi Biologics? | Wuxi Biologics's last 12 months FCF is $174M. |
| What is Wuxi Biologics's FCF margin? | Wuxi Biologics's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Wuxi Biologics? | Current FCF multiple of Wuxi Biologics is 75.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
